AusperBio
Develops oligonucleotide therapeutics targeting chronic hepatitis B
$120MSeries C
Role not disclosedYV
YuanBio Venture Capital
Activity from announced rounds
Activity in this selectionrialto-venture-capital-8865d6c3
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $171M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionBeyang Therapeutics
AI-driven drug discovery company using its ExCEED molecular design platform
$30MSeries A
Role not disclosedCORE Biomedicine
Developing the next generation of precision medicines by going beyond genomics.
$21MSeries A
Role not disclosed